Crispr Therapeutics shares tumble after significant earnings miss
Rambus INC (NASDAQ:RMBS) SVP, General Counsel John Shinn, sold 790 shares of common stock on August 4, 2025, for $74.6138 per share, totaling $58,944. The transaction comes as Rambus trades near its 52-week high of $76.20, having delivered an impressive 79% return over the past year. According to InvestingPro data, the company maintains strong fundamentals with an 82% gross profit margin and excellent financial health scores.
Following the transaction, Shinn directly owns 20,188 shares of Rambus INC. The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission. InvestingPro analysis shows the stock is trading near its Fair Value, with 16 additional exclusive insights available to subscribers through detailed Pro Research Reports.
In other recent news, Rambus Inc . has reported notable financial performance in its recent earnings announcements. The company exceeded revenue expectations for the first quarter, posting $170 million compared to the anticipated $167 million, alongside earnings per share of $0.60, surpassing the forecast of $0.58. However, in the second quarter of 2025, Rambus experienced a mixed outcome with earnings per share falling short at $0.53 against a forecast of $0.58, while revenue exceeded expectations at $172.2 million, above the predicted $166.97 million. Analysts have taken note of these developments, with Susquehanna raising its price target for Rambus to $75, maintaining a Positive rating due to strong intellectual property growth. Similarly, Rosenblatt increased its price target to $90 from $80, keeping a Buy rating, and highlighted Rambus as a significant player in enhancing AI system performance. These recent developments underscore the company’s strategic positioning and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.